Summary & Overview
Peripheral Vascular Disorders without CC/MCC: Inpatient Reimbursement Overview
DRG 301 encompasses inpatient stays for peripheral vascular disorders without Complication or Comorbidity or Major Complication or Comorbidity, covering conditions such as peripheral arterial disease and select venous disorders that do not carry additional coded complications. This Diagnosis-Related Group matters for inpatient reimbursement because it defines a lower-severity payment tier under Medicare prospective payment, affecting hospital payment and resource allocation for vascular care.
DRG 301 Overview
DRG 301 covers inpatient admissions for peripheral vascular disorders without Complication or Comorbidity or Major Complication or Comorbidity, typically including patients treated for peripheral arterial disease, claudication, noncritical limb ischemia, venous disorders, or related vascular conditions that do not require escalation for comorbid complications. This Diagnosis-Related Group groups cases with relatively lower resource use compared with higher-severity peripheral vascular Diagnosis-Related Groups and therefore influences base payment determinations under Medicare inpatient prospective payment. Understanding this grouping is important for hospitals and coders because case assignment affects reimbursement and comparative utilization metrics. The classification is based on principal diagnosis, procedures performed, and the absence of Complication or Comorbidity and Major Complication or Comorbidity codes.
Clinical Trials
- Investigational endovascular techniques for limb ischemia: Trials focusing on novel minimally invasive endovascular interventions (e.g., new catheter-based atherectomy or angioplasty technologies and adjunctive imaging guidance) enroll patients hospitalized with symptomatic peripheral arterial disease causing rest pain or tissue loss but without major complications. These studies evaluate procedural success, limb salvage rates, and short-term perioperative safety metrics in patients who would typically be assigned to this DRG, and are relevant to providers and payers because they may affect length of stay, resource use in the acute inpatient setting, and downstream need for repeat procedures or higher-acuity care.
- Comparative effectiveness studies of medical management strategies: Prospective or pragmatic trials comparing intensive medical optimization (antiplatelet and lipid management strategies, supervised exercise initiation during admission) versus standard care in patients admitted for peripheral vascular disorders without major complications assess functional outcomes, wound healing, and readmission rates over months. This research addresses whether enhanced inpatient-focused secondary prevention and discharge planning reduce 30- and 90-day readmissions and progression to more serious ischemia, information that influences inpatient clinical pathways and payer decisions about covering bundled care or transitional services.
- Post-discharge outcomes and care coordination research: Observational cohort studies and implementation research tracking patients after discharge examine rates of outpatient follow-up, adherence to vascular-risk modification, ambulatory wound care utilization, and long-term limb outcomes in this lower-acuity DRG population. These studies identify gaps in transitions of care, social determinants affecting recovery, and predictors of avoidable readmissions or escalation to CC/MCC-level care, offering actionable data for hospitals and payers to design discharge interventions, case management programs, and value-based payment models tailored to this group.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.